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Minimal residual disease (MRD) in acute myeloid leukemia (AML) is a 
complex, multi-modality assessment and much as its clinical implications at 
different points are extensively studied, it remains even now a challenging area. 
It is the disease biology that governs the modality of MRD assessment; in patients 
harboring specific molecular targets, high sensitivity techniques can be applied. 
In AML patients undergoing allogenic hematopoietic stem cell transplantation 
(alloHSCT), relapse in considered as leading cause for treatment failure. In post-
transplant setting, regular MRD status assessment enables to identify patients at 
risk of impending relapse when early therapeutic intervention may be beneficent. 
We analyzed data of AML patients who underwent matched unrelated donor 
(MUD) HSCT since the introduction of this procedure in the Republic of North 
Macedonia. Chimeric fusion transcripts were identified in three patients; two of 
them positive for RUNX-RUNX1T1 transcript and one for CBFB-MYH11. One 
patient harbored mutation in the transcription factor CCAAT/enhancer binding 
protein α (CEBPA). Post-transplant MRD kinetics was measured by quantitative 
polymerase chain or multiplex fluorescent-PCR every three months after the 
transplantation during the first two years after the transplant. MRD negativity was 
achieved in three patients by the sixth month of HSCT, who were pre-transplant 
MRD positive. They sustained hematological and molecular remission for 19, 
9 and 7 months, respectively. The forth patient died due to transplant-related 
complication. Our experience suggests, when molecularly-defined AML patients 
undergo HSCT, regular MRD monitoring helps predict impending relapse and 
direct future treatment strategies.
Keywords: minimal residual disease (MRD), molecular monitoring,  
matched unrelated donor (MUD) hematopoietic stem cell transplantation (HSCT), 




1.1 Acute myeloid leukemia (AML)
Acute myeloid leukemia (AML) is a heterogeneous malignant disease of the 
hematopoietic system, marked by mutational arrest of myeloid lineage precursor 
cells and limited myeloid differentiation capacity [1]. Theoretically, malignant 
transformation can arise at any level at which cell precursors are capable of self-
renewal. However, the hematopoietic precursors are typically arrested in the earliest 
stages of myeloid maturation pathway - myeloblasts or promyelocytes. The malig-
nant cells suppress the normal hematopoiesis by accumulating in the bone marrow 
and displacing the normal hematopoietic stem cells, resulting in depletion of normal 
blood cells. Тhe presence of more than 20% myeloblasts in the bone marrow or 
peripheral blood, as assessed by morphological evaluation of blood smears and bone 
marrow aspirate smears is diagnostic for AML. Morphologically, AML cells resemble 
normal myeloblasts to some extent, although they are distinguished by specific 
features, such as Auer Bodies – crystalloid azurophylic granules or Auer Rods – 
needle-shaped conglomerates of granules. Immunophenotyping, cytogenetics and 
molecular genetics must be employed to confirm the diagnosis of AML and further 
characterize the AML subtype [1].
AML is one of the most common types of leukemia in adults, as stated by 
American Society of Cancer, the second most common, following chronic lym-
phocytic leukemia (CLL), but the leading cause of mortality of leukemic deaths 
[2]. The median age at diagnosis is approximately 70 years. The estimated annual 
age-standardized incidence rate is 4.3 per 100.000, more precisely, from 1.3 per 
100.000 in patients younger than 65 years and 12.2 per 100.000 in patients older 
than 65 [2, 3].
The etiology of de novo cases of AML is quite obscure. Only a small portion of 
all AML cases - around 10%, are secondary AML, due to transformation of prior 
hematological malignancy, such as myelodisplastic syndrome (MDS) or myelopro-
liferative neoplasm (MPN). Around another 10% of all cases arise from suggested 
DNA damage of known previous factor, as prior therapy with alkylating agents or 
topoisomerases, or prior radiotherapy [4].
1.2 WHO classification of AML
The revised fourth revision to the World Health Organization classification of 
Tumors of Hematopoietic and Lymphoid Tissues, published in 2017, distinguishes 
six AML subtypes and it incorporates cytogenetic and molecular abnormalities 
into diagnostic algorithms, in contrast to previous classifications of AML, based on 
morphology and immunophenotype [5]. The entity “AML with recurrent genetic 
abnormalities” comprises 11 subcategories of AML, with acute promyelocitic leu-
kemia (APL with PML-RARA) included. The abnormalities that are not included 
in this group are considered to be rare among adult population. Six well-defined 
recurrent balanced translocations and inversions and their variants are covered 
within this classification. Two entities included are new provisional subcategories: 
AML with BCR-ABL1 fusion gene and AML with mutated RUNX1. Although a 
matter of long-time controversy, de novo BCR-ABL+ AML is now classified as 
distinct AML subtype. However, current data show that BCR-ABL occur primarily 
in AML with antecedent myeloid disorder, such as myelodysplasia-related changes 
[6]. The cytogenetic and molecular abnormalities included in this classification are 
summarized in Table 1.
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1.3 AML risk categories
Current AML risk categorization follows the latest 2017 European LeukemiaNet 
(ELN) recommendations and is based on pretreatment genetic abnormalities. It is 
designed for risk-adapted treatment approach of patients with AML, conforming 
to their molecular profiles [7]. Three risk categories are recognized: favorable risk, 
intermediate risk and adverse risk group [7]. However, the prognostic significance 
of genetic abnormalities should be only analyzed in association/codependence with 
other patient-related or disease-related prognostic factors. Increasing age is corre-
lated with poor prognosis for two reasons; not only the poorer performance status in 
older age groups and the increased risk of toxicity and treatment-related mortality, 
but also the increased probability of previous underlying malignancy such as MDS 
or MPN, associated with adverse cytogenetic and higher risk of treatment resis-
tance. Furthermore, the presence of two genetic abnormalities simultaneously and 
their interactions can result in different prognostic impact, depending on the pres-
ence or the absence of another. The best studied example is the NPM1-FLT3-ITD 
interaction. As shown in Table 1, mutated NPM1 in the absence of a FLT3-ITD or 
presence of FLT3-ITD with a low allelic ratio is related to favorable prognosis, while 
the high allelic ratio of FLT3-ITD relocates it in the intermediate risk group. To the 
contrary, not mutated NPM1, or wild-type NPM1 in the absence of a FLT3-ITD or 
low allelic ratio FLT3-ITD is considered as intermediate risk group and finally, wild-
type NPM1 plus high allelic ratio of FLT3-ITD carries adverse prognosis [8]. ELN 
risk categories are presented in Table 1 in association with WHO classification of 
AML. In addition to those abnormalities, mutations in RUNX1, mutations in ASXL1 
and in TP53 convey particularly poor prognosis [9]. In regards to AML-karyotype, 
complex karyotypes and monosomal karyotypes, specific aneuploidies, such as 
deletion of chromosome 5 and chromosome 7 or 5q, 7q deletion, predict adverse 
prognosis in AML patients. These are often associated with TP53 mutations [10].
AML with recurrent genetic abnormalities adapted from 4th revised 
WHO classification 2017
Risk group, as per 2017 ELN 
stratification
Cytogenetic abnormality Molecular abnormality




t(9;11)(p21.3;q23.3) MLLT3-KMT2A AML Intermediate





AML with mutated NPM1 Favorable if without FLT-ITD 
or with FLT-ITD low
Intermediate if FLT-ITH high
AML with biallelic mutations of 
CEBPA$
Favorable
*Inv(3)(q21.3q26.2) results in reposition of a distal GATA2 enhancer to activate MECOM expression, not a fusion 
gene.
$Mutated CEBPA is associated with biallelic mutations of the gene, not a single mutation.
Table 1. 
Recurrent cytogenetic and molecular abnormalities in AML (4th revision of WHO classification, published in 
2017) and ELN risk categories.
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2.  The role of allogeneic hematopoietic stem cell transplantation 
(alloHSCT) in AML
Allogeneic hematopoietic stem cell transplantation plays a key role in the man-
agement of patients with AML, making it one of the commonest indications for 
alloHSCT. By overcoming the limitations of donor availability and the increasing 
pool of donors in the recent decades on one hand and improving the transplant 
procedures and post-transplant strategies on the other, alloHSCT evolved into a 
definitive curative option for a significant number of AML patients [11]. The major 
challenge remains the identifying the allo-mandatory patients who are likely to 
benefit from an allograft.
2.1 Matched related sibling and unrelated donor SCT in AML
The search for a compatible hematopoietic stem cell donor is based on the 
human leukocyte antigen (HLA) profile of the patient undergoing SCT. The 
preferred donor type for SCT is a matched sibling donor (MSD), bearing the most 
favorable outcome; however only about a third of all patients have an available 
sibling donor. Histocompatibilty antigens are co-dominantly expressed and are 
inherited following Mendelian rules of inheritance, which means there is only a 
25% likelihood of a patient and their sibling inheriting the same parental haplo-
types. Assuming an average of 2 to 3 children per family in European countries 
it has been estimated that a patient seeking a transplant has a 30% likelihood of 
having a matched sibling donor and therefore a 70% likelihood that the same 
patient will need a transplant from an unrelated donor. Since the world’s first donor 
registry was founded in 1974, WMDA nowadays comprises of 75 hematopoietic 
stem cells donor registries from 53 countries, with more than 33.573.307 volunteer 
donors listed up to date. (https://statistics.wmda.info). The coordination between 
the transplant centers is facilitated through donor registries. The unrelated donor 
search procedure commences with a formal search request which is sent to the 
national registry, which further undertakes the responsibilities in all steps until the 
graft distribution [12]. The process of an unrelated donor search and activation is 
completed in 2 months on the average and up to 10 weeks.
2.1.1 The “ideal” unrelated donor profile
The general recommendation is selection of a 10/10 HLA-matched unrelated 
donor whenever possible (in loci HLA A, HLA B, HLA C, HLA DR and HLA 
DQ ). The second best choice would be 9/10 identical unrelated donor. HLA typ-
ing is necessary to be performed at high-resolution level by using next-generation 
sequencing (NGS) or sequencing-based typing (SBT) as preferable typing method. 
As published by Lee et al. 2007, HLA mismatch in any of non-permissive or high-
risk alleles: HLA A, B, C and DRB1 results in 10% decrease in survival probabilities 
for each mismatch in transplanted patients at early disease stage, and even worse at 
advanced disease stage [13]. Donor associated features may narrow down the choice 
of suitable unrelated donor. At the time of recruitment, donors are assessed in order 
to exclude medical conditions or habits that can possibly cause harm to transplant 
recipient, in particular – their history of infectious diseases, inherited, autoimmune 
and malignant diseases. According to WMDA recommendations a minimum donor 
blood-borne infectious disease markers testing is suggested, including serology for 
hepatitis B and C, HIV, syphilis and HTLV1/2. Those recommendations are adapted 
in line with local polices as additional endemic transmissible diseases may also be 
covered [14]. The donor’s age is considered an important factor, probably the most 
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powerful one; younger donors are associated with better prognosis with a 5.5% 
increase in the hazard ratio for overall mortality for every 10-year raise in donor age 
[15]. Donor registries recruit donors between 16 and 55 years and almost half of the 
registered donors registered are younger than 35. Diverse data on the impact of sex 
mismatch and blood group incompatibility are been reported, emphasizing the cor-
relation with other factors, such as conditioning regimen or stem cell source. Donor 
CMV serum-positivity is a negative prognostic factor for transplant outcome. It 
appears however, that not the CMV serum-negativity, but a matched patient/donor 
CMV serum status determines the transplant outcome more significantly [16].
2.2 Haploidentical related donors
The recent improvements in transplant technologies have led to the consider-
ation of using a haploidentical related donor when HLA- matched sibling or HLA-
matched unrelated donor is not available. It is estimated that around a half of the 
patients in need of a transplant have rare haplotypes and HLA-matched donor can-
not be found in donor registries. In the past, the major inquiry in terms of haploi-
dentical setting has been the expected high rate of GVHD. On the contrary, over the 
past few years, the use of post-transplant cyclophosphamide on day +3 and day +4 
after the transplant, has significantly decreased the rate of acute and chronic GVHD 
and nowadays haploidentical HSCT is established transplant method for patients 
lacking HLA-matched donor [17]. Even more, numerous retrospective studies have 
shown similar outcomes for MUD – SCT and haploidentical HSCT [18].
2.3 Umbilical cord blood transplantation
The first umbilical cord blood transplantation (UCBT) was successfully 
performed in 1988, in a 5-year-old child, diagnosed with Fanconi Anemia, using 
HLA-matched sibling, an older brother. Subsequently, in the following years, UCB 
transplants were encouraged in the pediatric population for the treatment of malig-
nant and non-malignant hematological diseases, using both related and unrelated 
donors. Therefore, data on UCBT mainly originate from procedures performed 
in children. The major limitations of this procedure are delayed engraftment and 
delayed immune reconstitution, leading to severe and often fatal infections [19]. 
However, during the past few years, as mismatched transplant activity increases, 
UCBT is progressively superseded by haploidentical HSCT.
3. The role of minimal residual disease (MRD) in AML
In AML patients, a complete hematological remission is defined as total recovery 
of blood counts, less than 5% blasts in bone marrow and recovery of heamato-
poiesis of all cell lineages, as assessed by cytomorphological examination [20]. 
Morphological assessment of post-therapy disease status is limited to 100–400 
nucleated cells and can identify the presence of leukemic cells to levels of 1:20 white 
blood cells (WBC). Besides the small number of analyzed cells another limitation 
of cytomorphology is the subjective component and the inaccuracy in distinguish-
ing normal from leukemic myeloblasts [21]. Limitations of cytomorphological 
assessment were partially overcome by the introduction of highly sensitive methods 
able to detect the smallest residual leukemic cells populations or minimal (measur-
able) disease. Minimal residual disease (MRD) indicates presence of leukemic cells 
at levels of 1:104 to 1:106 WBC. MRD detection in AML is necessary for various 
reasons. Firstly, it is an objective, well-defined post-treatment method to establish 
Acute Leukemias
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a remission status at deeper level. Secondly, it is a powerful tool for risk stratifica-
tion of AML and guiding treatment approach. And finally it enables identifying 
impending relapse in AML patients in complete remission [22–24]. Several studies 
have so far reported a positive correlation between the MRD positivity and the risk 
of relapse and shorter survival rate, compared to MRD negative AML patients. This 
refers to MRD status during and after post-remission chemotherapy, as well as prior 
and after SCT [24–33]. However, AML is a malignancy with complex molecular 
landscape and despite the fact that genetic aberrations are shown to be powerful 
prognostic determinants none of them have been ascertained to accurately predict 
the outcome [9]. No guidelines or recommendations are available so far on when 
and how to implement MRD assessments and on how to apply the results to clinical 
practice. According to ELN recommendations, during the treatment phase MRD 
should at least be assessed at the following time points: at the time of diagnosis, 
after 2 cycles of standard induction/consolidation chemotherapy and after the end 
of the treatment. For patient candidates for allo-HSCT, an MRD assessment should 
be carried out after the last chemotherapy, not exceeding 4 weeks of the initiation 
of the conditioning regimen [22].
3.1 MRD in AML patients undergoing allo-SCT
In a post-transplant setting, the primary importance of MRD evaluation is 
to detect impending relapse and thus to identify patients who may benefit from 
early clinical intervention [22–24]. The continual death rate due to relapse after 
allo-SCT is discouraging, even despite the changing landscape of AML and novel 
treatment paradigms. Data from the Center for International Blood and Marrow 
Transplant Research (CIBMTR) report 63% mortality rate in patients undergoing 
unrelated donor HSCTs due to transplant-related events including graft-vs.-
host disease, infection and other causes-organ toxicity or second malignancies, 
compared to 37% of deaths due to relapse [34]. This high relapse ratio suggests 
that there are residual leukemic cell populations that have survived therapy, 
capable of causing relapse, referred to as measurable or minimal residual disease. 
These cell subsets are believed to be present even up to several months before 
apparent morphological disease, at a time when they can be solely detected by 
high sensitivity methods.
3.2 Methods for MRD assessment
A number of methods are employed for MRD measurement but is the biology 
of the disease itself that governs the modality of MRD assessment. The complexity 
of AML, the myriad of genetic aberrations and the diversity of immunophenotypes 
restrain the recognition of uniform approach for MRD detection. In addition, as 
per Butturini A, the of MRD detection in AML is altered by the size of the tested 
sample, sample source (blood, bone marrow) and the time point of sample obtain-
ing rather than the sensitivity of the employed method for MRD assessment, due 
to the heterogeneous distribution of residual leukemic cells and the fluctuating 
expression of the MRD target [24]. In general, two methods are commonly incor-
porated into clinical routine: multiparameter flow cytometry (MFC) which allows 
detection of aberrant immunophenotypes and molecular methods by using tumor-
specific molecular primers, such as RT-qPCR or multiplex fluorescent- [22, 24]. 
MFC affords relative sensitivity of 1:10−3. The main constrains of this method are 
that not all leukemia cells present aberrant immunophenotypes and that the initial 
phenotypes may change through disease evolution and clone selection [35].
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3.2.1 Molecular MRD in AML patients
Two approaches are available for molecular MRD monitoring. The first one is 
real-time PCR-based and the second is by using sequencing techniques. PCR-based 
MRD assessment affords sensitivity of 1:10−5 to 1:10−6, which means 100–1000 
fold greater than other methods applied. Therefore, it is the ELN-recommended 
platform for molecular monitoring in AML due to the established high sensitivity 
[22, 24]. However, considering the molecular heterogeneity of AML, it is restricted 
to less than half of patients (35% in older patients as their frequency decreases 
with age); those harboring specific molecular targets that can be tracked for MRD 
monitoring, including mutations, translocations, inversions, deletions and poly-
morphisms. More precisely, PCR-based MRD monitoring is proposed for AML with 
validated molecular markers, such as mutations in the gene encoding nucleophos-
min (NPM1) and the chimeric fusion genes RUNX1- RUNX1T1, CBFB-MYH11 and 
PML-RARA [24, 25]. For these mutations, standardized PCR-assays are employed 
with well-defined threshold levels [36]. In contrast, the use of the mutations in 
FLT3-ITD, FLT3-TKD, NRAS, KRAS, DNMT3A, ASXL1, IDH1, IDH2, MLL-PTD, 
EVI1 and WT1 as single MRD markers is not recommended because of frequent 
losses or gains of certain mutations at relapse. These markers could be used in 
combination with a second MRD marker if present [22].
ELN defined the molecular responses for patients in complete hematological 
remission after completing chemotherapy or after a performed transplant proce-
dure [22]. Complete molecular remission is defined by two successive MRD negative 
samples in an interval of a minimum of 4 weeks. Molecular persistence at low copy 
numbers is defined as presence of 100–200 copies/104 ABL copies corresponding to 
<1–2% of target to reference gene or allele burden; and a copy number or increase of 
more than 1 log between 2 MRD positive samples. Molecular progression is defined as 
an increase of MRD copy numbers >1 log10 between 2 positive samples. And finally, 
molecular relapse is an increase of MRD copy numbers >1 log10 between 2 positive 
samples in a patient who previously achieved MRD negativity.
In our practice, MRD assessment, using RT-PCR is routinely performed in AML 
patients with genetic aberrations. MRD is measured during and after post-remis-
sion chemotherapy, and in patients undergoing SCT prior the transplant procedure 
and at précised time points during the post-transplant period. However, in this 
paper, we focus on the molecular monitoring in patients undergoing MUD – HSCT, 
diagnosed with AML with specific genetic aberrations. We present here our find-
ings at four AML patients and our initial experiences. Specific recommendations for 
molecular follow-up in AML-patients harboring these aberrations and the clinical 
implication of MRD status in post-transplant period will be discussed in line with 
our results.
4.  Molecular monitoring in patients undergoing allo-SCT: single center 
experience
4.1 Case definition
Since the introduction of MUD-HSCT in the Republic of North Macedonia in 
November 2018, 10 AML patients underwent MUD HSCT until June 2020. Of those 
ten, molecular markers were identified in a total of 4 patients; two patients were 
positive for RUNX-RUNX1T1 transcript, 1 patient for CBFB-MYH11 transcript and 
1 patient had mutation in CEBPA gene. The medical records of these patients were 
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reviewed for initial findings, clinical manifestations, clinical course, treatment regi-
men and outcome. Patients’ individual characteristics are summarized in  
Table 2. Two patients were diagnosed with “de novo” AML and the other two 
patients had secondary AML evolving from antecedent myelodysplasia and 
myeloid sarcoma, respectively. All patients were transplanted in first complete 
hematological remission. Three patients received conditioning regimen consid-
ered myeloablative [37] with Bu-Cy + ATG and the one patient received reduced 
intensity chemotherapy regimen with Bu-Flu + ATG [37]. In all patients, peripheral 
blood stem cells were used as graft source. The patients underwent HSCT between 
November 2018 and January 2020. During the post-transplant period, bone marrow 
samples for MRD monitoring were obtained at scheduled time points - the first one 
within two months of HSCT and thereafter at +3, +6, +9 and + 12 months of HSCT 
[38] (Figure 2). The cut-off date for follow-up was June 30, 2020. Median follow-up 
time was 8 months (range: 3–19 months).
4.2 Samples
Samples of 5–10 ml of bone marrow aspirate in EDTA were used for PCR 
based analyses. PCR analyses were performed at the Center for Biomolecular 
Pharmaceutical Analyses - UKIM-Faculty of Pharmacy – Skopje.
4.2.1 Molecular PCR based methods (RT-PCR and multiplex fluorescent PCR)
Post-transplant MRD kinetics was evaluated by using quantitative polymerase 
chain reaction (RT-qPCR) or multiplex fluorescent-PCR every three months after the 
transplantation. Molecular analyses were performed at the Center for Biomolecular 
Pharmaceutical Analyses, UKIM-Faculty of Pharmacy, Skopje in bone marrow 
aspirates. RT- PCR is a high sensitivity method to detect the presence of leukemia 
cells down to levels of 1:10−5 to 1:10−6 white blood cells (WBC) [22, 36]. Mononuclear 
cells (MNCs) were isolated by Ficoll density gradient. Detailed procedures for MRD 
Patient 1 Patient 2 Patient 3 Patient 4
Age at diagnosis 22 21 58 37
Sex male male female Female
Comorbidities no no no No
2017 ELN risk 
stratification16









Number of induction 
therapies
2 2 3 (2 + 1) 2
Number of consolidation 
therapies
2 2 2 2
Time to HSCT 6 months 7 months 15 months 6 months
Disease status prior 
HSCT
CR1 CR1 CR1 CR1
MRD status prior HSCT MRD + (0.15%) MRD + 
(0.20%)
MRD + MRD + 
(0.09%)
Table 2. 
Individual and clinical pre-HSCT characteristics of analyzed AML patients.
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Figure 1. 
MRD analyses using the AML-ETO hybrid transcript (A, B, C) or CEBPA mutation (D, E) molecular 
markers performed at diagnosis (a and D), pre-transplantation (B) and one month after transplantation (C 
and E). The blue circles and red squares in (A), (B) and (C) indicate the strength of the fluorescent signal 
generated during the RT/PCR amplification of the internal control ABL and hybrid AML-ETO transcripts, 
respectively. The arrow in (D) indicates the detection of the 5 bp-del mutant allele in the CEBPA gene.
Acute Leukemias
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assays detecting RUNX1-RUNX1T1, CBFB-MYH11 and CEBPA gene mutations have 
been published by the Europe Against Cancer Initiative [22]. The samples were run 
in triplicate. The molecular response was expressed as log reduction of transcript 
levels. MRD positivity was defined according to the Europe Against Cancer Program 
Criteria (amplification in at least 2 out of 3 replicates with cycle-threshold values 
of 40 or less, using a threshold setting of 0.1) [22]. The presence of mutations in 
the CEBPA gene was evaluated by multiplex fluorescent PCR analysis covering the 
coding region of the CEBPA gene and the exact molecular defects of all additional 
fragments was analyzed by Sanger sequencing [23]. Representative results of these 
analyses for the detection of the AML-ETO hybrid transcript and the mutation in the 
CEBPA gene are shown in Figure 1.
4.3 Pre-transplant MRD status
Molecular screening at the time of diagnosis is carried out in almost all our 
patients with newly diagnosed AML. Bone marrow samples are routinely investi-
gated for RUNX1-RUNX1T1, CBFB-MYH11 and PML-RARα fusion transcripts, as 
well as single gene alterations, such as insertions in exon 12 in NPM1, FLT3 tandem 
duplication in exon 12, and deletions/insertions in CEBPA gene. All here presented 
patients were tested for the initial aberration prior to transplant procedure (median 
time = 13 days; range: 9–14 days). All patients were MRD positive (0.15%; 0.20% 
and 0.09% in patient 1, 2 and 4 respectively). In patient 3, presence of 5 bp deletion 
in CEBPA gene was confirmed.
4.4 Clinical histories
4.4.1 Case I
A young man at the age of 22 was diagnosed in March 2018 with myeloid 
sarcoma after surgically resection of the intestinal tumor mass. Three months later, 
the disease progressed in AML and standard induction chemotherapy regimen 
3 + 7 DA (anthracycline plus ARA-C) was initiated. Molecular evaluation of the 
bone marrow showed expression of the CBFB-MYH11 inv.(16) (p13;22) fusion 
transcript. Remission was achieved after second induction and two consolida-
tion therapies with high dose ARA-C were administered [1, 7]. The patient had 
a HLA haploidentical sibling. Unrelated 10/10 HLA matched donor, registered 
to PL-DKMS (Fundacija DKMS) was activated and allo-SCT was performed in 
November 2018 [14–16]. The patient received myeloablative conditioning regimen 
with Bu/Cy + ATG and conventional immunosuppressive therapy with cyclospo-
rine and methotrexate was applied [33]. Peripheral blood stem cells (PBSC) were 
used as graft source at a total dose of 4,6 × 106 CD34+ cells/ kg. In post – transplant 
period, CBFB-MYH11 inv.(16) (p13;22) was used as a molecular MRD target [22]. 
On day +45 of HSCT, an increased MRD load, compared to that of pre-transplant 
MRD was documented. Consequently, the initial dose of 100 mg was reduced to 
75 mg per day. Оn day +90 of HSCT, molecular MRD negativity was confirmed 
and continuously preserved up to the last evaluation at +15 months after HSCT. 
Immunosuppression was discontinued in December 2019, after completing one 
year of HSCT. Molecular MRD kinetics of CBFB-MYH11 inv. (16) (p13;22) in this 
patient is shown in Figure 2. Complete donor chimerism was first documented 
on day +90 and maintained to follow-up cutoff date. As this patient initially 
manifested extramyeloid presentation of AML, we did a PET scan assessment, at 
12 months after HSCT and no pathological accumulation or activity were observed.
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4.4.2 Case II
A previously healthy young man at the age of 21 was diagnosed with AML 
in January 2019. Initial findings of bone marrow revealed presence of RUNX1-
RUNX1T1 fusion transcript. Remission was achieved after two cycles of standard 
DA (7 + 3) induction regimen and two consolidation therapies with high dose 
ARA-C were administered [1, 7]. MUD HSCT was performed in August 2019 after 
conditioning with Bu/Cy + ATG regimen [37]. Unrelated HLA 10/10 identical 
donor, signed to the German National Bone Marrow Donor Registry (DE-ZKRD), 
was activated [14–16]. A total of 5,2 × 106 peripheral blood stem cells/ kg were 
infused. MRD was measured by using RT- PCR, first on day +45 and thereafter at 
every three months. Up to the sixth month of HSCT, relatively steady kinetics of 
transcript levels was noted as shown at Figure 2. By gradual reduction of immuno-
supression dose, molecular remission was documented at +6 month of HSCT and at 
+9 months consecutively. Complete donor chimerism was first documented on day 
+90 and maintained to the final evaluation at +9 months.
4.4.3 Case III
A 58-year-old woman was diagnosed with refractory anemia-myelodysplastic 
syndrome (MDS) in July 2018 and rapid progression into overt acute leukemia was 
demonstrated 4 months later. Initial molecular analysis detected 5 bp deletion in 
CEBPA gene. Induction chemotherapy (DA 7 + 3) was initiated and bone marrow 
evaluation showed no signs of remission after two cycles induction chemothera-
pies [1, 7]. Remission was achieved after one cycle salvage chemotherapy with 
FLAG-Ida regimen [7, 11]. Two consolidation therapies with high dose ARA-C were 
administered. MUD HSCT was performed in November 2019. Due to the patient 
age, reduced intensity chemotherapy (RIC) regimen was preferred, consisting of 
Busulfan and Fludarabin + ATG (fludarabine 30 mg/m2 i.v for 5 days – from −8 to 
−4 and Busulfan 3.5 mg/kg/day for 2 days: day −5 and day −4) [37]. Unrelated HLA 
10/10 identical donor from The Italian Bone Marrow Donor Registry (IBMDR) 
was activated [14–16]. Peripheral blood stem cells were used at a dose of 6,9 × 106 
CD34+ cells/kg. MRD was first assessed on day +60 and the next one on day +120 
with the last one assessed on day +150. Absence of previously detected deletion was 
confirmed on the first assessment, coupled with complete donor chimerism.
Figure 2. 
Molecular MRD monitoring of patients with identified chimeric fusion transcripts. MRD kinetics of patients 1, 




A 37-year-old woman was diagnosed with RUNX1-RUNX1T1- mutated 
AML in July 2019. Treatment was initiated with DA (7 + 3) induction regi-
men and complete remission was established after two induction cycles [1, 7]. 
Two consolidation therapies with high dose ARA-C were applied afterwards. 
Unrelated HLA 10/10 identical donor, recruited through the German National 
Bone Marrow Donor Registry (DE-ZKRD) was activated and MUD HSCT was 
performed in January 2020 [14–16]. Peripheral blood stem cells were used as a 
source and a high number of HSC were harvested - 9 × 106 CD34+ cells/kg.  
Myeloablative regimen with Bu/Cy + ATG was used [37]. Conventional immu-
nosuppressive therapy with cyclosporine and metothrexate was used. No sig-
nificant complications were observed in the early post-transplant period [38]. 
Bone marrow evaluation was performed at +1 month of HSCT when complete 
donor chimerism was documented. She was MRD positive with MRD loads, 
nearly equal to those measured in pre-transplant evaluation (MRDv = 0.1% and 
MRDV = 0.09% respectively). On day +38 of HSCT, she appeared with symp-
toms of lower gastrtointestinal acute GvHD grade III, subsequently confirmed 
histologically. Immunosuppressive therapy with high dose methylprednisolone 
was immediately started. Three days later, she manifested acute severe respira-
tory symptomatology, leading to respiratory insufficiency and fatal outcome on 
day +45 of HSCT.
4.5 Post-transplant molecular monitoring
During the post-transplant period, in line with EBMT recommendations  
[38, 39], chimerism and molecular MRD status were assessed every three 
months and up to one year of HSCT, starting within two months of HSCT 
(45 days median time) [7, 24, 25]. In patient 1, a significantly increased MRD 
load was observed on day +45 of HSCT, compared to pre-transplant MRD load 
(0,6% and 0,15% respectively) and we reduced the immunosuppression dose. 
Immunosuppressive therapy is designed to prevent GvHD, but it also inhibits 
graft-versus leukemia effects (GvL). This patient had no previous signs of GvHD, 
thus he was carefully monitored for possible occurrence of new ones. Our objec-
tive was to enhance GvL effects, without causing serious GVHD, which resulted 
in achieving MRD negativity at +90 days of HSCT and maintaining it for a year 
so far in absence of GvHD manifestations. In patient 2, molecular loads kinetics 
showed a relatively steady curve, almost identical MRD values were measured 
until the sixth month of HSCT, when molecular negativity was documented. 
Patients 1, 2 and 3 had been followed up for 19 months of HSCT, 9 and 8 months 
respectively. They are in complete hematological and molecular remission for 
13, 3 and 6 months, as defined by International Working Group for Diagnosis, 
Standardization of Response Criteria, Treatment Outcomes, and Reporting 
Standards for Therapeutic Trials in Acute Myeloid Leukemia: completely recovery 
of peripheral blood cells, <5% blasts in bone marrow, disappearance of the cells 
with previously documented leukemic immunophenotype and disappearance of 
previously detected molecular mutation [39]. Patient 4 died on day +45 of HSCT 
due to transplant-related complication. MRD status was assessed on day +30 of 
HSCT, when she was MRD positive with low MRD loads, equal to those prior 
to HSCT. Chimerism analyses in all patients, including patient 4 on day +30 of 
HSCT, documented early complete donor chimerism, which remained sustained 
during the follow-up evaluations in the first 3 patients.
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5. Discussion
5.1 RUNX1-RUNX1T1- mutated AML
Chimeric fusion genes CBFB-MYH11, RUNX1-RUNX1T1, including PML-
RARα, represent about 25% of AML cases, so called core-binding AML. As stated 
before, RUNX1-RUNX1T1-mutated AML is stratified into favorable risk group 
and therefore, patients harboring this mutation often do not undergo HSCT in 
first CR. Results from AML Study group show that half of these patients relapse 
very soon, almost all during the first year of completion of therapy [31]. In com-
parison, according to a single center study, among transplanted patients with 
RUNX1-RUNX1T1- AML, only 10–20% are expected to experience relapse [29]. 
RUNX1-RUNX1T1 transcript is well established powerful marker to predict risk 
of post-transplant relapse and direct future clinical interventions. In line with 
the same study [29, 33], RUNX1-RUNX1T1 levels kinetics can accurately predict 
forthcoming relapse, but not late relapse, due to the narrow time lag from molecular 
to morphological relapse. For this reason, time intervals between MRD assessments 
in these patients should not exceed 3 months.
5.2 CBFB-MYH11 - mutated AML
Acute myeloid leukemia (AML) with inv.(16)/ t(16,16), leading to specific CBFB-
MYH11 fusion transcript formation is also considered as favorable subtype [32, 33].  
Therefore, in terms of transplantation, the same views are held as for RUNX1-
RUNX1T1- AML [29–31]. Due to the general low incidence of this subtype, as well asa 
lower transplant rate in this group, all data originate from small sample-studies. Such 
limited data suggest that post-transplant MRD is predictive of relapse in contrast to 
pre-transplant MRD. The strongest predictive value is seen at +3 months of HSCT and 
it is thought that this period of time reflects the sensitivity of leukemia cells toward 
the transplant [32]. In regards to the optimal time intervals between MRD assessments 
in these patients, according to some published data [33], CBFB-MYH11 AML relapses 
appear to be generally indolent, with the longest delay of 8 months from molecular 
relapse to hematological evident relapse. However, these findings cannot be taken for 
granted, as the study involved non-transplanted patients.
5.3 AML with CEBPA aberrations
CEBPA aberrations can be found in up to 10% of patients with AML. Apart from 
AML, these mutations and deletions can also occur in MDS, multiple myeloma and 
non-Hodgkin’s lymphoma (NHL) patients. CEBPA mutations result in functional 
block in myeloid differentiation and turning toward the erythroid lineage, with 
consequent erythroid hyperplasia or dysplasia, as was the case with our patient at 
the time of initial hematological assessment [40]. The most cases of CEBPA-mutant 
AML are double-mutated and exhibit two mutations and less than one third are 
single mutants. As per previously published data, double mutants have favorable 
prognosis, while the prognostic significance of single mutations is still unclear and 
it is codependent of the presence of additional gene mutations, such as FLT3-ITD 
and NPM1 and it is influenced by the karyotype [23, 40].
5.4 MRD and chimerism
In addition, in malignant diseases, chimerism kinetics seems to be remarkably 
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indirect marker for post-transplant MRD monitoring, it serves more likely as prog-
nostic factor for impending relapse. Therefore, chimerism analyses in bone marrow 
samples should be combined with MRD assessment in order to optimize the predic-
tive value. As per EBMT recommendations, chimerism status should be evaluated at 
the same time points as MRD status during the post-transplant follow-up, or more 
precisely, within the first month of HSCT and at every three months during the first 
and the second year of HSCT [38, 39].
MRD status can be used to guide future clinical interventions in the post-trans-
plant period. The presence of post-transplant MRD can identify those patients who 
are unlikely to benefit from re-application of similar therapies, because of selection 
and expansion of therapy-resistant clones. Different therapy strategies may be 
adopted in an attempt to eliminate MRD, varying from watchful waiting, through 
withdrawal of immunosuppression to more aggressive clinical interventions, distin-
guishing two general approaches - immunomodulation and chemotherapeuteic agents 
[41]. Immunomodulation includes donor lymphocyte infusion (DLI), natural killer 
(NK) cell infusion, both focused on enhancing GvL effects and chimeric antigen 
receptors (CAR) T-cells. In addition, emerging new chemotherapeutic agents such 
as DNA hypomethylating agents and targeted therapies could potentially eradicate 
MRD positivity [42].
6. Conclusion
Since major advancement had been achieved in the field of molecular monitoring, 
molecular MRD analyses became widely incorporated into the clinical routine and 
the decision making-process. PCR is currently used in our clinical practice in patients 
expressing specific molecular targets undergoing both autologous and allogeneic 
HSCT. Post-transplant molecular monitoring is of twofold significance: predicting 
impending relapse and guiding future MRD-based decisions and treatment strate-
gies. In patients undergoing allogeneic HSCT, MRD should be evaluated within a 
month prior to the start of the conditioning regimen. During the follow-up period, 
MRD should be monitored every three months in a BM sample for at least two years 
and according to individual risk thereafter. MRD status itself is not a conclusive or a 
sufficient criterion to decide to intervene therapeutically. The main inquiry remains 
whether, when and at what thresholds a clinical intervention is required. Well-
designed prospective clinical trials are needed to provide answers to these questions 
and establish MRD- guided clinical protocols.
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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